Migraine headaches cause substantial financial and social costs to migraine headache sufferers, their families, and their friends.
Lost Income. The average migraine sufferer
loses 19.5 days of work each year due to absenteeism and reduced efficiency caused by migraine headaches. 1
| Annual Salary* |
Income Lost |
| $30,000 ($15.00/hour) |
$2,340 |
| $40,000 ($20.00/hour) |
$3,120 |
| $50,000 ($25.00/hour) |
$3,900 |
| $60,000 ($30.00/hour) |
$4,680 |
| $70,000 ($35.00/hour) |
$5,460 |
| $80,000 ($40.00/hour) |
$6,240 |
| $90,000 ($45.00/hour) |
$7,020 |
| $100,000 ($50.00/hour) |
$7,800 |
Prescription Medication Costs. The average migraine headache sufferer, who regularly uses prescription medications, spends over $1,500 per year on prescription medications, 3,** an average of
over $125 per month.
Impact on Social Life. Among a national sample of migraine headache sufferers,
61% believed that their families were significantly affected by their migraine headaches, including delay in accomplishing household duties and activities with children (62%) and spouses (69%); a substantial proportion reported cancellation of pleasure trips, celebrations and social activities. 2
SootheAway can reduce severity of migraine headaches and lessen the time needed to
recover from migraine pain. As a result, SootheAway can:
- Reduce the number of work days lost and improve efficiency in the workplace
- Provide relief when prescription medications are unavailable or ineffective
- Provide migraine sufferers with more time to spend with family and friends
* Annual salary based on 50 weeks of work per year and 40 hours per week.
** SootheAway is not, and does not claim to be, a substitute for prescription medication.
- 1 Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC (2001) The multinational impact of migraine symptoms on healthcare utilization and work loss. Pharmacoeconomics 19:197–206
- 2 Smith, R. Impact of migraine on the family. Headache. 1998;38:423-426
- 3 Etemad LR, Yang W, Globe D, Barlev A, Johnson KA (2005) Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm 11:137–144
